Diagnostics (Basel)
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey.
Published: March 2025
Low bone mineral density (BMD) is common in hemophilia patients. Identifying high-risk patients for low BMD early is essential to prevent complications and reduce morbidity. The parathyroid hormone (PTH)/calcium (Ca) ratio is a cost-effective marker for predicting BMD, highlighting the need for routine screening and early intervention in this population. Hemophilia is a hereditary bleeding disorder caused by deficiencies in clotting factors VIII (hemophilia A) and IX (hemophilia B). Patients with hemophilia are at risk of low bone mineral density (BMD). This study aimed to evaluate the prevalence of low BMD, associated risk factors, and raise awareness regarding its significance in hemophilia patients. We retrospectively assessed bone metabolism in 62 hemophilia patients followed at our center. BMD was evaluated using dual-energy X-ray absorptiometry (DEXA). Additionally, serum levels of 25-OH-D3, alkaline phosphatase, PTH, Ca, phosphor, and creatinine were measured. The PTH/Ca, PTH/25-OH-D3, and Ca×25-OH-D3/PTH ratios were calculated. The median age of the 62 patients with hemophilia included in the study (hemophilia A: 87.1%, hemophilia B: 12.9%) was 37 years (range: 21-66), and all were male. Of these patients, 67.7% ( = 42) had severe, 21% ( = 13) had moderate, and 11.3% ( = 7) had mild hemophilia. A total of 85.5% of patients were on factor prophylaxis, and 75.4% had a target joint. In laboratory analysis, the median 25-OH-D3 level was 13.4 µg/L and 75% patients had 25-OH-D3 deficiency. According to DEXA results, 62.9% had lower than normal BMD. When we divided the patients into normal and low BMD groups according to DEXA results, weight ( = 0.006), height ( = 0.024), factor levels ( = 0.004), PTH ( = 0.010), AST ( = 0.029), and PTH/Ca ( = 0.011) levels were statistically significantly different between the groups. The severity of the disease and the rate of receiving prophylaxis were higher in the group with low BMD ( = 0.015, = 0.006, respectively). In multivariate analysis, PTH/Ca ratio and weight were found to be independent risk factors for BMD. A linear relationship was found between PTH/Ca ratio and BMD. The optimal cut-off value for PTH/Ca was 6.57, with a selectivity of 65% and specificity of 82%. When we divided the patients into groups according to the cut-off value of 6.57, we found that the probability of low BMD increased approximately 7-fold in the group with PTH/Ca > 6.57 (OR 7.045, 95% CI 1.485-33.42, = 0.014). There was an inverse association between patient weight and low BMD ( = 0.043). Low BMD is a critical public health concern frequently observed in patients with hemophilia. The study highlights a high rate of low BMD and 25-OH-D3 deficiency in hemophilia patients, with the PTH/Ca ratio shown to be useful in predicting BMD. The PTH/Ca ratio is suggested as an accessible, cost-effective, and practical test for evaluating BMD in hemophilia patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3390/diagnostics15050638 | DOI Listing |
The objective of this study was to validate the usefulness of the W-index (WI) for screening patients at risk of osteoporosis by correlating the WI results with those obtained from peripheral dual-energy X-ray absorptiometry (pDXA). The W-index is based on oblique line contrast on panoramic radiographs, in which the pixel intensity of the oblique line is compared with the pixel intensity of adjacent structures at the mandibular ramus. A total of 333 patients with panoramic radiographs and pDXA results were evaluated according to T-score results and WI measurements.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
March 2025
Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Background: A20, also known as TNF-α-induced protein 3 (TNFAIP3), is a crucial negative regulator of inflammation and immune responses. Emerging evidence suggests that A20 is involved in the regulation of glucose metabolism and plays a significant role in bone metabolic diseases by inhibiting nuclear factor (NF)-κB activation. However, the potential relationship between serum A20 level and bone mineral density (BMD) in patients with type 2 diabetes mellitus (T2DM) has not been explored.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
March 2025
Department of Urology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
Objective: Osteoporosis (OP) and urolithiasis (UL) are two metabolic diseases that are prevalent globally. Previous observational studies have found a relationship between these two diseases that increases the risk of each other, but whether there is a direct causal link is still unclear. Currently, research on the mechanisms of these two diseases mainly focuses on external factors such as diet and environment.
View Article and Find Full Text PDFInt J Mol Sci
February 2025
i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.
The introduction of CFTR modulators in the clinics has improved body mass index in cystic fibrosis (CF) individuals. Leptin is a major regulator of appetite and energy expenditure but is also involved in bone metabolism. Whether circulating leptin levels are associated with low bone mineral density (BMD) and fracture risk in CF remains unknown.
View Article and Find Full Text PDFDiagnostics (Basel)
March 2025
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey.
Low bone mineral density (BMD) is common in hemophilia patients. Identifying high-risk patients for low BMD early is essential to prevent complications and reduce morbidity. The parathyroid hormone (PTH)/calcium (Ca) ratio is a cost-effective marker for predicting BMD, highlighting the need for routine screening and early intervention in this population.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.